



Independent licensees of the Blue Cross and Blue Shield Association

Medication Policy Manual

Policy No: dru345

Topic: Non-Preferred Branded DPP4-Inhibitor-Containing Medications:
-alogliptin (Nesina[®], Kazano[®], Oseni[®])
-linagliptin (Tradjenta[®], Jentadueto[®])

Date of Origin: May 9, 2014

Committee Approval Date: July 14, 2017

Next Review Date: July 2018

Effective Date: August 1, 2017

IMPORTANT REMINDER

This Medication Policy has been developed through consideration of medical necessity, generally accepted standards of medical practice, and review of medical literature and government approval status.

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control.

The purpose of Medication Policy is to provide a guide to coverage. Medication Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care.

Description

Alogliptin (Nesina[®]), linagliptin (Tradjenta[®]), and saxagliptin (Onglyza[®]) are oral medications used for the treatment of type 2 diabetes. They block the dipeptidyl peptidase-4 (DPP-4) enzyme. By blocking this enzyme, insulin production increases, glucose production in the liver goes down, and blood sugar levels decrease. Combination products containing these medications include: alogliptin/ metformin (Kazano[®]), alogliptin/ pioglitazone (Oseni[®]), and linagliptin/ metformin (Jentadueto[®]).

Policy/Criteria

- I. Most contracts require prior authorization approval of alogliptin- and linagliptin-containing medications prior to coverage. These medications may be considered medically necessary for the treatment of type 2 diabetes when criteria A, B, and C below are met.
- A. Treatment with metformin is contraindicated, not tolerated, or has been ineffective after 90 days of therapy.
- AND**
- B. Treatment with a sitagliptin-containing medication (e.g. Januvia, Janumet, Janumet XR) is contraindicated, not tolerated, or has been ineffective after 90 days of therapy.
- AND**
- C. Treatment with a saxagliptin-containing medication (e.g. Onglyza, Kombiglyze) is contraindicated, not tolerated, or has been ineffective after 90 days of therapy.
- II. Administration, Quantity Limitations, and Authorization Period
- A. Regence Pharmacy Services considers alogliptin- and linagliptin-containing medications to be a self-administered medication.
- B. When prior authorization is approved, non-preferred DPP-4 inhibitor-containing medications may be authorized in quantities as follows:
1. Alogliptin (Nesina): 30 tablets per month
 2. Alogliptin/ metformin (Kazano): 60 tablets per month
 3. Alogliptin/ pioglitazone (Oseni): 30 tablets per month
 4. Linagliptin (Tradjenta): 30 tablets per month
 5. Linagliptin/ metformin (Jentadueto): 60 tablets per month
- C. Authorization may be reviewed at least annually to confirm that current medical necessity criteria are met and that the medication is effective.
- III. Alogliptin- and linagliptin-containing medications are considered investigational when used for any condition other than type 2 diabetes, including, but not limited to:
- A. Pre-diabetes/ prevention of diabetes
 - B. Weight loss
 - C. Metabolic syndrome
 - D. Polycystic Ovary Syndrome
 - E. Type 1 diabetes or diabetic ketoacidosis

Position Statement

Summary

- Metformin (along with lifestyle changes) is the best value for the initial treatment of type 2 diabetes, with proven efficacy and safety track record.
- DPP4-inhibitors are treatment options when metformin results in inadequate glucose lowering or is not tolerated.
- Among the DPP4-inhibitors, sitagliptin and saxagliptin are the best value for members.
- The safety and effectiveness of DPP4-inhibitors in conditions other than type 2 diabetes have not been established.

Background

- The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) have published a joint position statement on the management of type 2 diabetes. [1, 2]
 - * Glycemic targets and glucose-lowering therapies must be individualized; however diet, exercise, and education remain the foundation of any type 2 diabetes treatment program.
 - * The recommended therapy for newly diagnosed type 2 diabetes includes using metformin in addition to lifestyle interventions.
 - * Metformin can lower A1C by about 1.8% compared to placebo and preliminary data suggest there are some potential cardiovascular benefits.
 - * If a goal A1C of $\leq 7\%$ is not achieved, then the addition of one or more oral or injectable agents from other classes is reasonable, depending on individual patient considerations. Of note, SGLT2-inhibitors are not included in the ADA guidelines as a treatment option.
 - * Ultimately, many patients will require insulin therapy alone or in combination with other agents to maintain glucose control.
 - * Comprehensive cardiovascular risk reduction (e.g. controlling blood pressure, cholesterol, and smoking cessation) must be a major focus of therapy.

Goal of Treatment

- The American Diabetes Association has set an A1C treatment goal for patients with diabetes to not exceed 7%. [1]
 - * Lowering A1C to below or around 7% has been shown to reduce microvascular and neuropathic complications of type 1 and type 2 diabetes.
 - * Large-scale, randomized controlled trials have failed to find a significant long-term benefit of intensive glycemic control (A1C goals less than 6.5%) for lowering cardiovascular (macrovascular) risk. [1, 3-5]
 - * Intensive glycemic control (A1C goals less than 6.5%) may increase mortality in some patients. [3]

- The American Association of Clinical Endocrinologists (AACE) treatment guidelines suggest an A1C treatment target for patients with diabetes of 6.5%. However, this goal must be customized for the individual patient in consideration of factors such as comorbid conditions, duration of diabetes, history of hypoglycemia, hypoglycemia unawareness, patient education, motivation, adherence, age, limited life expectancy, and use of other medications.^[6, 7]

Clinical Efficacy

- DPP4-inhibitors lower A1C compared to placebo by 0.3% to 0.8%, but they have not been proven to reduce complications of diabetes. ^[9-12]
- Metformin can lower A1C by about 1.8% compared to placebo and is associated with reducing complications of diabetes. ^[8]
- There are no clinical studies establishing conclusive evidence of macrovascular risk reduction with DPP4-inhibitors. ^[9-12]
- There are no clinical trials that have demonstrated a superior benefit of DPP4-inhibitors over first line therapies such as metformin (see Appendix 1).
- There is no evidence that one DPP4-inhibitor is more effective than another.
- A high-quality systematic review of DPP4-inhibitors concluded that, in patients with type 2 diabetes who do not achieve the glycemic targets with metformin alone, DPP4-inhibitors can lower A1C in a similar way to sulfonylureas or pioglitazone, with neutral effects on body weight. Increased costs of the DPP4-inhibitors and unknown long-term safety continue to be concerns regarding their use. ^[24]

Safety

- The most common adverse reactions (reported in $\geq 5\%$ of patients treated with DPP4-inhibitors and more commonly than in patients treated with placebo) are: upper respiratory tract infection, headache, and nasopharyngitis. ^[9-12]
- The prescribing information for DPP4-inhibitors includes a warning regarding severe and disabling arthralgia and the risk of acute pancreatitis. Risk of acute pancreatitis is small and likely a class effect, which has been appreciated with more extensive post-marketing clinical experience. The FDA is currently reviewing all incretin mimetics (DPP-4 inhibitors and GLP-1 agonists) for risk of pancreatitis and pancreatic cancer. Saxagliptin- and alogliptin-containing medications also have a warning for the risk of heart failure in patients who have known risk factors for heart failure. ^[9-12, 25,26]

Dosing

- The recommended dose of alogliptin (in patients with an estimated creatinine clearance ≥ 60 mL/min) is 25 mg once daily, either as monotherapy or combination. ^[9]
 - * In moderate renal insufficiency (CrCl ≥ 30 mL/min to <60 mL/min), the dose of alogliptin should be 12.5 mg once daily. ^[9]
 - * In severe renal insufficiency (CrCl < 30 mL/min), or with ESRD requiring hemodialysis or peritoneal dialysis, the dose of alogliptin should be 6.25 mg once daily. ^[9]

- The recommended dose of linagliptin is 5 mg once daily, either as monotherapy or combination. No dosage adjustment is needed for renal or hepatic impairment. ^[10]
- The safety and effectiveness of higher doses have not been established.

Investigational Conditions

- Prediabetes / Prevention of Diabetes / Metabolic Syndrome
 - * There are no clinical trials that have demonstrated that DPP4-inhibitors can prevent or delay the development of type 2 diabetes.
 - * DPP4-inhibitors have not been proven to improve health outcomes in the treatment of “metabolic syndrome”.
- Weight Loss
 - * Some medications used for the management of diabetes, such as DPP4-inhibitors and GLP1-agonists, have been associated with weight loss in clinical studies. It is unknown, however, if the observed weight reductions are clinically relevant and result in improved health outcomes.
- Polycystic Ovary Syndrome
 - * There are no reliable clinical trials that have shown DPP4-inhibitors to be beneficial in the management of polycystic ovary disease.
- Type 1 Diabetes / Diabetic Ketoacidosis
 - * There are no well-designed, randomized controlled trials that demonstrate a benefit to using DPP4-inhibitors in type 1 diabetes.
 - * The FDA approved prescribing information for DPP4-inhibitors states that they should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. ^[9-12]

Appendix 1: Comparison of Product Information Reported Reductions In A1C (Monotherapy Only)

[8-23]

Drug	Baseline A1C (%)	Duration of Trial	Mean change from baseline (%)	Placebo Corrected change in A1C (%)
<i>Biguanide</i>				
metformin (Glucophage[®], generic) up to 2550 mg per day	8.4	29 weeks	-1.4	-1.8
<i>Dipeptidyl Peptidase-4 (DPP-4) Inhibitors</i>				
alogliptin (Nesina[®]) 12.5 mg to 25 mg once daily	7.9	26 weeks	-0.6	-0.6
linagliptin (Tradjenta[®]) 5 mg once daily	7.7 to 8.6	18 to 104 weeks	-0.4 to -0.7	-0.6 to -0.7
saxagliptin (Onglyza[®]) 2.5 mg to 5 mg once daily	7.9 to 8.0	24 weeks	-0.4 to -0.5	-0.6
sitagliptin (Januvia[®]) 100 mg once daily	8.0	18 to 24 weeks	-0.5 to -0.6	-0.6 to -0.8
<i>Glucagon-like Peptide-1 (GLP-1) Agonists</i>				
albiglutide (Tanzeum[®]) up to 50 mg weekly (with metformin)	8.1	104 weeks	-0.6	-0.9
dulaglutide (Trulicity[™]) up to 1.5 mg weekly (with metformin)	7.6	26 weeks	-0.9 to -1.1	-0.8 to -1.0
exenatide (Byetta[®]) up to 10 mcg twice daily (with metformin)	8.2 to 8.3	30 weeks	-0.4 to -0.8	-0.5 to -0.9
exenatide ER (Bydureon[®]) 2 mg once weekly (with metformin)	8.6	26 weeks	-1.5	N/A [†]
liraglutide (Victoza[®]) up to 1.8 mg once daily (with metformin)	8.3 to 8.4	26 weeks	-1.0	-1.1
<i>Meglitinide</i>				
repaglinide (Prandin[®]) up to 4 mg daily	8.5	12 weeks	-0.6	-1.7
<i>Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors</i>				
canagliflozin (Invokana[®]) up to 300 mg once daily	8.01	26 weeks	-1.03	-1.16
dapagliflozin (Farxiga[™]) up to 10 mg once daily	8	24 weeks	-0.9	-0.7
empagliflozin (Jardiance[®]) up to 25 mg once daily	7.9	24 weeks	-0.7	-0.7
<i>Sulfonylurea</i>				
glimepiride (Amaryl[®], generic) 8 mg once daily	unknown	14 weeks	unknown	-2.0
<i>Thiazolidinedione (TZD)</i>				
pioglitazone (Actos[®], generic) 30 mg to 45 mg daily	10.2 to 10.3	26 weeks	-0.3 to -0.9	-1.0 to -1.6

*Note: Data are pooled from separate studies or product literature and not necessarily comparable

† No placebo-controlled trials available

Cross References
Non-Preferred Branded GLP1-Agonist-Containing Medications, dru347
SGLT2-Inhibitor-Containing Medications, dru506

Codes	Number	Description
N/A		

References

- American Diabetes Association. 2017 Standards of medical care in diabetes. *Diabetes Care*. January 2017 vol. 40 Supplement 1 S1-S132.
- Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: Update to a Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2015;38:140-9. PMID: 25538310.
- Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 358:2545–2559, 2008
- Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 358:2560–2572, 2008
- Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med*. 2009 Jan 8;360(2):129-39.
- Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2017 executive summary. *Endocr Pract*. 2017;23:207-238. PMID: 26731084.
- Tamez-Pérez HE, Proskauer-Peña SL, Hernández-Coria MI, Garber AJ. AACE Comprehensive Diabetes Management Algorithm 2013. *Endocrine Practice*. *Endocr Pract*. 2013 Jul-Aug;19(4):736-7. doi: 10.4158/EP13210.LT. PubMed PMID: 23807530.
- Glucophage [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, Inc.; April 2017.
- Nesina [package insert]. Deerfield, IL: Takeda Pharmaceuticals; December 2016.
- Tradjenta [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. March 2017.
- Onglyza [package insert]. Princeton, NJ: Bristol-Meyers Squibb; February 2017.
- Januvia [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; January 2017.
- Tanzeum [package insert]. Research Triangle Park, NC: GlaxoSmithKline, Inc.; September 2016.
- Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; January 2017.
- Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc.; February 2015.
- Bydureon [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc.; September 2015.
- Victoza [package insert]. Princeton, NJ: Novo Nordisk Inc.; April 2017.
- Prandin [package insert]. Princeton, NJ: Novo Nordisk, Inc.; February 2017.
- Invokana [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; February 2017.
- Farxiga [package insert]. Princeton, NJ: Bristol-Meyers Squibb; March 2017.
- Jardiance [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; December 2016.
- Amaryl [package insert]. Bridgewater, NJ: Aventis Pharmaceuticals Inc.; December 2016.
- Actos [package insert]. Lincolnshire, IL: Takeda Pharmaceuticals America, Inc.; November 2013.

24. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. *BMJ*. 2012 Mar 12;344:e1369. doi:10.1136/bmj.e1369. PubMed PMID: 22411919.
25. FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. [cited 4/1/2013]; Available from: <http://www.fda.gov/Drugs/DrugSafety/ucm343187.htm>
26. FDA Drug Safety Communication: Diabetes medications containing saxagliptin and alogliptin: risk of heart failure. [cited 04/22/2016]; Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Revision History

Revision Date	Revision Summary
07/14/2017	Removed Onglyza and Kombiglyze XR from policy (now a preferred brand).
05/13/2016	No changes to coverage criteria with this annual update